Health Atlas
Menu
Evidence-led reference

Prevention & care

Bias in health research: selection, measurement, missing results and uncertain direction

10 sources · Latest source check 2026-10-20 UTC
On this page

Bias is a systematic departure from the intervention effect a sound comparison would estimate. The RoB 2 framework evaluates a particular trial result through several domains. Calling a study “randomized” does not settle every domain or every outcome.[1]

Different mechanisms can threaten different results

Different mechanisms can threaten different results
MechanismIllustrative concernInterpretation limit
ConfoundingTreatment groups differ in causes of the outcomeAdjustment depends on relevant information and assumptions[2]
SelectionEntry or inclusion depends on relevant post-intervention factorsStudy size does not itself remove selection problems[2]
Missing outcome dataObserved participants may differ from those missingAmount alone does not settle the bias judgment[1]
Outcome measurementAssessment differs with knowledge of treatmentThe outcome and measurement process matter[1]
Selective reportingA result is selected from several possible analysesA published result may not represent all results[4]

A risk-of-bias judgment concerns a result and its question

RoB 2 separates randomization, deviations from intended interventions, missing outcomes, outcome measurement and selection of the reported result. Different outcomes or analyses from one trial can therefore need different judgments. Its signaling questions structure assessment, rather than replace methodological reasoning. Incomplete reporting and actual flawed methods are related but different issues; uncertainty about what happened should be identified. A journal label or general reputation cannot substitute for examining the result.[1]

Confounding is one mechanism rather than a synonym for all bias

The original ROBINS-I framework compares an observed intervention study with the hypothetical trial it seeks to emulate. It includes confounding, participant selection, intervention classification, deviations, missing data, measurement and reporting. A measured association can be distorted through several pathways, including ones that ordinary baseline adjustment does not solve. The framework’s target comparison and assumptions should be specified. It does not turn observational data into actual randomization or prove that a large adjusted analysis has removed every important difference.[2]

Assessment instruments have versions and stated limits

The developers’ November 2025 ROBINS-I V2 page identifies a revised draft for specific results from follow-up cohort studies. It describes changed domains, signaling questions and algorithms, and says refinements remain likely. That version should not be silently treated as identical to the 2016 instrument or as a final universal tool for every observational design. A report of a formal assessment needs the instrument version and rationale. This guide explains concepts without claiming to have performed that assessment.[3]

Missing evidence can concern a whole study or one result

ROB-ME addresses bias when entire studies or particular results are unavailable to a meta-analysis because of their P values, direction or magnitude. This is different from every instance of incomplete data within a trial. A search that finds many published reports can still miss unfavorable or unreported results. The tool structures judgments about the missing-evidence mechanism rather than assuming that every unavailable report has a known finding. Funding and disclosure information can prompt scrutiny, but an allegation alone cannot quantify this mechanism or replace result-specific assessment.[4]

A known tendency does not determine one observed result

Jurek and colleagues distinguish bias, defined across repeated studies, from an individual estimate that also varies through random error. Their methodological analysis shows why nondifferential exposure misclassification alone does not guarantee an association is underestimated. Even when additional conditions imply average bias toward no association, a particular observed estimate can overshoot because of chance. “The error affects both groups” is therefore insufficient to declare a result conservative. Bias direction and random uncertainty need separate reasoning tied to the actual measurement process.[5]

Three meanings behind missing data

Missing-data labels concern why a value is unavailable, not simply how many records are missing. In these terms, “random” has a statistical meaning.[10]

Mechanisms depend on relationships with the data
TermMeaning
Missing completely at random (MCAR)Missingness is unrelated to observed or unobserved values.[10]
Missing at random (MAR)After conditioning on observed variables, missingness no longer depends on the unobserved value.[10]
Missing not at random (MNAR)Missingness still depends on unobserved values after accounting for observed variables.[10]

Evidence & uncertainty

The large MetaBLIND analysis did not detect an average treatment-effect difference according to blinding status. This null comparison does not establish that blinding is irrelevant in every trial; the authors identify methodological uncertainty and retain its importance.[8]

Selected-source overview · Independent review pending

Published questions

Does randomization eliminate every risk of bias?

Selected-source overview · Independent review pending. Read the evidence context.

No. RoB 2 also considers deviations, missing outcomes, measurement and result selection. Assessment concerns a specified result rather than the design label alone.[1]

Evidence behind this answer
  • RoB 2: a revised tool for assessing risk of bias in randomised trials

    original risk of bias framework · 2019
    Original indexed abstract and selected original indexed passages inspected; direct original page unavailable or challenge blocked; full text not independently inspected · Systematic deviation, result-level assessment, five domains and reporting-versus-conduct judgments

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Is all bias simply confounding between treatment groups?

Selected-source overview · Independent review pending. Read the evidence context.

No. ROBINS-I distinguishes confounding from selection, classification, missing data, measurement and reporting problems. They can require different assumptions and assessments.[2]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Is the posted ROBINS-I V2 draft identical to the original tool?

Selected-source overview · Independent review pending. Read the evidence context.

No. The developers describe changed domains and questions and identify the November 2025 version as a draft for cohort studies, subject to refinement.[3]

Evidence behind this answer
  • ROBINS-I V2 tool: November 2025 revised draft

    official original tool version notice · 2025
    Selected original official page passages inspected; not an independent clinical appraisal · Specific cohort-study result, changed questions/domains/algorithms and explicit draft status

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does a large set of publications establish that all relevant results are available?

Selected-source overview · Independent review pending. Read the evidence context.

No. ROB-ME addresses whole studies and within-study results missing because of their findings. Publication volume alone cannot settle that concern.[4]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does nondifferential measurement error guarantee a conservative observed association?

Selected-source overview · Independent review pending. Read the evidence context.

No. Jurek and colleagues explain why additional conditions and random variation matter. An average bias direction does not guarantee the direction of one estimate.[5]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Can the design-characteristic analysis supply one correction for every trial?

Selected-source overview · Independent review pending. Read the evidence context.

No. Associations varied by outcome and could reflect reporting or confounding. Average exaggeration is not a universal result-specific adjustment.[6]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Did the observer review establish the same distortion for every outcome?

Selected-source overview · Independent review pending. Read the evidence context.

No. Its selected within-trial comparisons support a concern about assessment bias, with variation and limits to transfer across outcomes and methods.[7]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does MetaBLIND prove blinding never matters?

Selected-source overview · Independent review pending. Read the evidence context.

No. Its average comparison was null with methodological uncertainty. A result-specific assessment remains necessary, and its design differs from within-trial assessor comparisons.[8]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does having a protocol guarantee that published outcomes are complete?

Selected-source overview · Independent review pending. Read the evidence context.

No. Chan’s protocol-to-publication comparison found reporting discrepancies. The existence of a protocol enables comparison rather than proving that reporting followed it.[9]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does “missing at random” mean follow-up was lost by pure chance?

Selected-source overview · Independent review pending. Read the evidence context.

No. Missing at random (MAR) allows missingness to depend on observed information. Its key assumption concerns what remains after accounting for that information.[10]

Evidence behind this answer
  • Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

    original statistical methods article · 2009
    Original PMC full article retrieved after native BMJ403; selected definitions, conditional assumptions, observed-data limits and funding/disclosures read. No software recipe, current implementation recommendation or complete-case universal rule adopted. · Consequences of missing data; Box1; statistical methods and multiple-imputation assumptions; funding/disclosures

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Reported trial features were associated with average exaggeration in one analysis

Savović and colleagues combined seven meta-epidemiological studies after removing overlap, yielding 234 unique meta-analyses and 1,973 trials. Inadequate or unclear sequence generation, concealment and double blinding were associated with average exaggeration, mainly for subjective outcomes. Evidence of bias was weaker for objective and mortality outcomes. These were observational comparisons of trial characteristics, not randomized assignments to poor methods. Incomplete reporting and confounding by other design features limit attribution. An average association cannot provide a fixed correction to every trial estimate.[6]

Within-trial assessor comparisons found evidence of observer bias

Hróbjartsson and colleagues reviewed trials assessing the same binary outcomes with blinded and nonblinded assessors. The main analysis included 21 trials and 4,391 patients and found average exaggeration with nonblinded assessment. Some proposed moderators did not show significant associations. This design is more direct than comparing unrelated trials but still concerns selected outcomes and assessment arrangements. It does not identify an identical amount of bias for every clinical measurement or establish that every nonblinded result must be wrong.[7]

A later broad comparison had a null average result

MetaBLIND analyzed 142 meta-analyses containing 1,153 trials and separated blinding of patients, care providers and outcome assessors. It found no evidence of an average effect-estimate difference between blinded and nonblinded trials. Uncertainty remained, and misclassification of blinding and residual confounding could obscure associations. This differs from the earlier within-trial assessor design. The studies can overlap in underlying evidence and are not experiments proving universal opposite rules. A null average comparison does not remove the need to consider the outcome and how knowledge could influence it.[8]

Protocol comparisons revealed selective outcome reporting

Chan and colleagues compared trial protocols with publications in a historical Danish cohort of 102 randomized trials. Statistically significant efficacy and harm outcomes were more likely to be fully reported than nonsignificant outcomes, and primary-outcome discrepancies were common. This is direct evidence about reporting in that cohort, not a prevalence estimate for every current journal or discipline. Protocols and registrations can help expose discrepancies, but their existence alone does not ensure complete reporting. The evidence supports investigating selection mechanisms rather than treating publication as proof of completeness.[9]

An observed explanation is an assumption

For example, missing blood-pressure measurements might depend on recorded age. Calling that MAR assumes age and other observed information explain the relevant missingness; it does not mean follow-up was lost by pure chance. Observed records alone cannot distinguish MAR from MNAR. Sensitivity analyses examine alternatives rather than prove which mechanism occurred.[10]

References

  1. RoB 2: a revised tool for assessing risk of bias in randomised trials

    Original risk of bias framework

    Sterne and colleagues · Content/publication date: 2019
    Accessed: 2026-10-14 UTC · Original indexed abstract and selected original indexed passages inspected; direct original page unavailable or challenge blocked; full text not independently inspected
    Cited sections: Systematic deviation, result-level assessment, five domains and reporting-versus-conduct judgments

    Original indexed framework passages inspected; direct BMJ 403. No complete independent formal RoB 2 application claimed. PMID 31462531 and DOI 10.1136/bmj.l4898 are one work; tool access routes are not a new allowance.

  2. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

    Original nonrandomized intervention bias framework

    Sterne and colleagues · Content/publication date: 2016
    Accessed: 2026-10-14 UTC · Original indexed abstract and selected original indexed passages inspected; direct original page unavailable or challenge blocked; full text not independently inspected
    Cited sections: Historical 2016 target-trial comparator and seven distinct domains

    Original indexed framework and introduction inspected; BMJ 403/PMC challenge. Describes the 2016 instrument, distinguished from posted V2 draft. PMID 27733354/PMC5062054/DOI are one original paper.

  3. ROBINS-I V2 tool: November 2025 revised draft

    Official original tool version notice

    ROBINS-I development group · Content/publication date: 2025
    Accessed: 2026-10-14 UTC · Selected original official page passages inspected; not an independent clinical appraisal
    Cited sections: Specific cohort-study result, changed questions/domains/algorithms and explicit draft status

    Original developer page and change summary inspected. Linked full instrument PDF not independently appraised; claims limited to page summary, version and purpose. Historical/current draft routes are one tool-version work allowance.

  4. ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis

    Original missing evidence bias framework

    Page and colleagues · Content/publication date: 2023
    Accessed: 2026-10-14 UTC · Original indexed abstract and selected original indexed passages inspected; direct original page unavailable or challenge blocked; full text not independently inspected
    Cited sections: Whole studies or particular results missing according to findings; structured mechanism-specific assessment

    Original indexed paper abstract/introduction and official developer notice inspected; no full-paper or independent tool application claimed. PMID 37984978/DOI/tool route share one publication allowance. Funding disclosure alone is not assigned a numerical bias effect.

  5. Proper interpretation of non-differential misclassification effects: expectations vs observations

    Original methodological analysis and simulation

    Jurek, Greenland, Maldonado and Church · Content/publication date: 2005
    Accessed: 2026-10-14 UTC · Original abstract and bibliographic record inspected; full study text not independently inspected
    Cited sections: Nondifferentiality, average bias versus sample error and non-guaranteed observed direction

    Original complete abstract and online date inspected; full paper is purchase-limited. Online March31 distinct from June issue. PMID 15802377/DOI 10.1093/ije/dyi060 and redirected publisher minimal page are one paper.

  6. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

    Combined meta epidemiological analysis

    Savović and colleagues · Content/publication date: 2012
    Accessed: 2026-10-14 UTC · Original abstract and bibliographic record inspected; full study text not independently inspected
    Cited sections: Seven studies/234 unique meta-analyses/1973 trials, subjective-versus-objective outcomes and confounding/reporting limits

    Original full abstract in author-agency record inspected. September 18 issue verified; earlier online day not independently established, so year precision retained. Related NIHR report PMID 22989478/NBK100892 describes the same analysis and is not independent replication or a second work allowance for these results.

  7. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors

    Systematic review of within trial assessor comparisons

    Hróbjartsson and colleagues · Content/publication date: 2012
    Accessed: 2026-10-14 UTC · Original indexed abstract and selected original indexed passages inspected; direct original page unavailable or challenge blocked; full text not independently inspected
    Cited sections: 21 trials/4391 patients, mean exaggeration, nonsignificant moderator comparisons and selected-outcome limits

    Original indexed abstract/method passages inspected. No full independent trial appraisal or universal bias correction claimed. BMJ e1119/PMID 22371859 and PDF route are one review.

  8. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study

    Meta epidemiological blinding comparison

    Moustgaard and colleagues; MetaBLIND investigators · Content/publication date: 2020
    Accessed: 2026-10-14 UTC · Original indexed abstract and selected original indexed passages inspected; direct original page unavailable or challenge blocked; full text not independently inspected
    Cited sections: 142 meta-analyses/1153 trials, differentiated blinding roles, null average comparisons and uncertainty

    Original indexed full abstract and original discussion/summary passages inspected; PMC7190062 direct challenge. Observational comparison of trial features differs from within-trial assessor studies. Shared primary-trial overlap remains possible; no universal no-bias conclusion.

  9. Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials: Comparison of Protocols to Published Articles

    Original protocol to publication cohort study

    Chan and colleagues · Content/publication date: 2004
    Accessed: 2026-10-14 UTC · Selected original full-text methods, results and limitations inspected; no independent systematic appraisal
    Cited sections: 102 historical Danish trials; significance-associated efficacy/harm completeness and primary-outcome discrepancies

    Selected original abstract, methods, tables and limitations inspected. Cohort approved 1994–1995, not a current universal prevalence estimate. PMID 15161896/DOI 10.1001/jama.291.20.2457 and publisher PDF are one paper.

  10. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

    Original statistical methods article

    Sterne JAC and colleagues · Content/publication date: 2009
    Accessed: 2026-10-20 UTC · Original PMC full article retrieved after native BMJ403; selected definitions, conditional assumptions, observed-data limits and funding/disclosures read. No software recipe, current implementation recommendation or complete-case universal rule adopted.
    Cited sections: Consequences of missing data; Box1; statistical methods and multiple-imputation assumptions; funding/disclosures

    Dated methods explanation; not an imputation recipe.

Scope & review

Population
Readers assessing particular trial or observational intervention results; selected historical methodological studies
Exposure or intervention
Selection/confounding, missing data, measurement, reported-result selection and missing evidence; tool versions and bias direction
Comparison
Actual or hypothetical sound comparison; within-trial blinded assessments versus observational comparisons across trial features
Outcomes
Distorted effect estimates, reporting completeness, between-study variation and uncertainty about direction
Timeframe
Original frameworks 2005–2023 and November 2025 ROBINS-I V2 draft; historical trial cohorts and meta-epidemiological samples
Jurisdiction
General research interpretation, not personal diagnosis or an Atlas formal risk-of-bias assessment. Tool/result/outcome/design scope and reporting limits are explicit

Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

Revision history
  • 2026-10-14 UTC: Added a bounded evidence-interpretation explainer; independent clinical review and comprehensive synthesis remain pending.
  • 2026-10-20 UTC: Added supported foundational, practical and evidence explanations after reading full target bodies and relevant current/pending adjacent coverage. Original sections, questions and sources preserved as exact prefixes; qualified review pending.

What this article still leaves open

  • Which specific mechanism could distort this outcome and analysis, and in which direction under plausible assumptions?
  • Does apparently missing information reflect poor reporting, flawed conduct or both?
  • How do tool-version changes and uncertain empirical averages affect a transparent result-specific judgment?
Suggest a correction

Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.